Erythrasma.

This case report describes well-demarcated brown plaques with overlying fine scale in the bilateral axillae, inframammary folds, and inguinal folds and widespread coral-red fluorescence.

Erythrasma.

THE COMPARISONA and B Axilla of a 65-year-old White man with erythrasma showing a well-demarcated erythematous plaque with fine scale (A). Wood-lamp examination of the area showed characteristic bright coral red fluorescence (B).C and D A well-demarcated, red-brown plaque with fine scale in the antecubital fossa of an obese Hispanic woman (C). Wood-lamp examination revealed bright coral red fluorescence (D).E Hypopigmented patches (with pruritus) in the groin of a Black man. He also had erythrasma between the toes.

Estudio clínico del eritrasma en pacientes diabéticos / Clinical study of Erythrasma in diabetic patients

Este estudio se realizó para caracterizar la frecuencia de aparición, extensión, edad y sexo de la incidencia del eritrasma en pacientes diabéticos según el tipo, la duración y el estado. Estudio transversal y combinado de casos y controles de 200 pacientes diabéticos y 160 grupos no diabéticos que visitaron la consulta externa del Hospital Docente Al-Saddar, Departamento de Medicina y Dermatología, desde el período de diciembre de 2019 a julio de 2020. Dentro del grupo con Diabetes las edades oscilan entre los 12 y los 60 años con una edad media de 37,6 años. 148 pacientes padecían diabetes mellitus tipo no insulinodependiente (NIDDM) y 52 pacientes padecían IDDM. Entre todos los pacientes diabéticos examinados con la lámpara de Wood, para detectar infección por eritrasma, 34 (17%) resultaron afectados, de 26 hombres (76,5% de los afectados) y 8 mujeres (23,5%) se vieron afectados. Entre los 52 pacientes con DMID, 15 (28,8%) se vieron afectados y sólo 19 (12,8%) del resto con DMID se vieron afectados. Se encontró que la incidencia máxima de edad se encuentra en la cuarta década (30-40 años). El sitio de mayor propensión de las lesiones parecía ser la ingle en un 100%. La forma extensa o generalizada se encontró solo en 3 (8,8%) pacientes y el sitio menos afectado fue la membrana de los dedos solo en 2 (5,9%). La presentación de los pacientes fue asintomática en 22 (64,7%) y el cambio de color (marrón rojizo) se encontró en todos los pacientes. En conclusión, la aparición de eritrasma en pacientes diabéticos es más frecuente que su aparición en pacientes no diabéticos. Existe una asociación significativa entre la aparición de eritrasma y la IDDM. La frecuencia de aparición de eritrasma aumenta con la larga duración de la DM y más con la DM incontrolada

This study was conducted to characterize the frequency of occurrence, extent, age, and sex incidence of Erythrasma in diabetic patients according to the type, duration, and state. A cross-sectional and case-control combined study of 200 diabetic patients and 160 non-diabetic groups visiting the outpatient clinic of Al-Saddar Teaching Hospital, Department of Medicine and Dermatology, from the period of December 2019 to July 2020. Among the diabetic group, their ages range from 12-60 years with a mean age of 37.6 years. 148 patients were non-insulin-dependent diabetes mellitus type (NIDDM) and 52 patients were IDDM. Among all the diabetic patients examined by wood's light to detected Erythrasma infection 34(17%) were found to be affected, from 26 males (76.5% of the affected) and 8 females (23.5%) were affected. Among the 52 patients with IDDM, 15(28.8%) were affected and only 19(12.8%) from the remainder with NIDDM affected. The peak age incidence was found to be in the fourth decade (30-40 y). The site of greatest propensity of the lesions appeared to be the groin was 100%. The extensive or generalized form was found only in 3(8.8%) patients and the least affected site was the toe webs only in 2(5.9%). The presentation of the patients was found to be asymptomatic in 22(64.7%), and the color change (red brown) was found in all of the patients. In the conclusion, the occurrence of Erythrasma in diabetic patients is more frequent than its occurrence in non-diabetic patients. There is a significant association between the occurrence of Erythrasma and the IDDM. The frequency of occurrence of Erythrasma increase with the long duration of DM and more with the uncontrolled DM.

Erythrasma in athletes and football players.

BACKGROUND: Erythrasma is a superficial skin infection that presents with red-brown, flaky macules. It is caused by the Gram-positive bacteria Corynebacterium minutissimum. The purpose of our study is to investigate the prevalence and incidence of erythrasma in active sportsmen, i.e., athletes and football players, comparing the results with the incidence of the disease in the general population. METHODS: A total of 140 sportsmen, 110 male athletes and 30 football players, were examined by clinical examination, microscopic examination (Gram staining), and Wood's lamp examination. RESULTS: Erythrasma was diagnosed in 39% (43) of the athletes and in 40% (12) of the football players studied. Inguinal folds were found to be most commonly affected. The disease was often localized to more than one area. This erythrasma study conducted in Bulgaria is the first in active athletes. The worldwide prevalence of erythrasma in the general population varies from 4 to 15%. CONCLUSION: It was found that the incidence of erythrasma is high in men actively involved in sports. The results obtained are explained by the presence of many factors predisposing for the development of this disease in the athletes.

Eritrasma / Erythrasma

No disponible

Persistent rash on feet.

A 49-year-old Hispanic woman presented with a 4-month history of scaling and a macerated rash localized between her toes. The rash was malodorous, mildly erythematous, and sometimes associated with pruritus. The patient had no relevant medical history. Potassium hydroxide testing was performed and found to be negative. So a Wood's lamp was used to examine the patient's toes--and it revealed the diagnosis. WHAT IS YOUR DIAGNOSIS? HOW WOULD YOU TREAT THIS PATIENT?

Erosio interdigitalis blastomycetica: A review of interdigital candidiasis.

Erosio interdigitalis blastomycetica (EIB) is a Candida infection affecting the third web space, between the third and fourth fingers. In 1915, Gougerot and Goncea first described saccharomycetic organisms isolated from the hands and feet. Johannes Fabry later named it in 1917, well before the genus Candida was introduced in 1923. EIB is most common among those who work with their hands frequently in water, such as dishwashers, launderers, bartenders, and homemakers. Clinical presentation most commonly consists of a central erythematous erosion surrounded by a rim of white macerated skin involving at least one interdigital web space. The differential diagnosis is narrow, consisting of irritant contact dermatitis (ICD), erythrasma, inverse psoriasis, and bacterial infection (i.e. impetigo). The diagnosis is made by clinical examination in addition to fungal culture and KOH testing. The prognosis is good and treatment options include avoidance of frequent water immersion and topical or oral antifungal agents. Suspicion for secondary infections such as erysipelas and cellulitis should remain high until lesions have resolved. This review aims to address the history, epidemiology, pathophysiology, histopathology, clinical presentation, differential diagnoses, diagnosis, prognosis, and management of EIB. It also suggests an alternative name in place of the current misnomer.

Erythrasma: A report of nine men successfully managed with mupirocin 2% ointment monotherapy.

BACKGROUND: Erythrasma is a benign dermatosis that typically occurs on intertriginous skin. PURPOSE: We describe a series of nine men with erythrasma that were successfully treated with mupirocin 2% ointment monotherapy. METHODS AND MATERIALS: We reviewed PubMed for the following terms: erythrasma, mupirocin, ointment, treatment. We also reviewed papers containing these terms and their references. RESULTS: Complete resolution of erythrasma occurred following monotherapy with twice daily application of mupirocin 2% ointment. CONCLUSIONS: Several topical and oral treatments are available to successfully manage erythrasma. Our series of patients with erythrasma experienced resolution with mupirocin 2% ointment treatment within 2 to 4 weeks of therapy. Monotherapy with mupirocin 2% ointment should be considered as a primary treatment alternative for erythrasma.

[Treatment of interdigital foot Erythrasma with ozonated olive oil]. / Tratamiento de eritrasma interdigital de pies con aceite de oliva ozonificado.

BACKGROUND: Erythrasma is caused by Corinebacterium minutissimum producing a porphyrin that with Wood's light emits a coral-red fluorescence. It is the most common bacterial infection of the feet. Ozonated olive oil decreases the cytoplasm and damages bacterial proteins and lipids. Treatment is with oral erythromycin and there is no consensus regarding the topical therapy of choice. The aim of this paper is to evaluate the therapeutic efficacy of ozonated olive oil in a pilot trial for Erythrasma. METHODS: Experimental, open, observational, descriptive, longitudinal clinical trial at the section of Mycology, of the General Hospital "Dr. Manuel Gea González". PATIENTS: 10 individuals with interdigital feet Erythrasma. INTERVENTION: ozonated olive oil every 12 hours for 10 days was given. RESULTS: All patients had disappearance of coral-red fluorescence, erythema, fissures, pruritus, and maceration; two patients persisted with scaling. A cure was obtained in 100 % of patients, similar to oral erythromycin response. CONCLUSIONS: Ozonated olive oil is a good topical treatment option for interdigital Erythrasma avoiding oral medications. Larger studies are required.

Introducción: el eritrasma es causado por Corinebacterium minutissimum que produce una porfirina que con la luz de Wood emite una fluorescencia rojo coral es la infección bacteriana más frecuente en los pies. El aceite de oliva ozononificado disminuye el citoplasma y daña las proteínas y los lípidos bacterianos. El tratamiento es mediante eritromicina oral y no hay consenso respecto a la terapia tópica de elección. El objetivo de este trabajo es evaluar la eficacia terapéutica del aceite de oliva ozonificado en el eritrasma en una prueba piloto. Métodos: estudio clínico experimental, abierto, observacional, descriptivo y longitudinal, llevado a cabo en la sección de Micología del Hospital General "Dr. Manuel Gea González". Se incluyeron 10 pacientes con eritrasma interdigital de pies, a quines se les administró aceite de oliva ozonificado cada 12 horas por 10 días. Resultados: en todos los pacientes hubo desaparición de la fluorescencia rojo coral, eritema, fisuras, prurito y maceración; en dos de ellos persistió la descamación. Se obtuvo una cura clínica en el 100 % de los pacientes, respuesta similar a la eritromicina oral. Conclusiones: el aceite de oliva ozonificado es una buena opción terapéutica tópica para el eritrasma interdigital, que permite evitar la prescripción de medicamentos por vía oral. Se requieren estudios más extensos.